Shares of Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN) have received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus price objective of $11.50 for the company and are expecting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also given Parnell Pharmaceuticals Holdings an industry rank of 177 out of 265 based on the ratings given to related companies.
A hedge fund recently bought a new stake in Parnell Pharmaceuticals Holdings stock. Sabby Management LLC bought a new stake in shares of Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 389,400 shares of the company’s stock, valued at approximately $635,000. Sabby Management LLC owned 2.93% of Parnell Pharmaceuticals Holdings as of its most recent filing with the SEC.
Parnell Pharmaceuticals Holdings (NASDAQ:PARN) opened at 1.4967 on Friday. The company’s market capitalization is $21.97 million. Parnell Pharmaceuticals Holdings has a 52 week low of $1.34 and a 52 week high of $4.89. The stock’s 50 day moving average price is $1.49 and its 200 day moving average price is $1.70.
About Parnell Pharmaceuticals Holdings
Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Parnell Pharmaceuticals Holdings Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parnell Pharmaceuticals Holdings Ltd and related companies with MarketBeat.com's FREE daily email newsletter.